Obinutuzumab (Gazyva) — CPB 0877 | AETNA Coverage Update

Aetna modified CPB 0877 for obinutuzumab (Gazyva), effective November 1, 2025. Here's what billing teams need to know before submitting claims under the updated criteria.

Aetna, a CVS Health company, updated its obinutuzumab coverage policy under Clinical Policy Bulletin CPB 0877 Aetna system, expanding covered indications across several B-cell lymphoma subtypes and chronic lymphocytic leukemia. The primary billing code affected is J9301 (injection, obinutuzumab, 10 mg), administered via infusion using CPT 96413 and add-on code +96415. If your oncology or hematology practice bills Aetna commercial plans for Gazyva, this update changes what you can get approved—and what documentation you need to back it up.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Obinutuzumab (Gazyva) — CPB 0877
Policy Code	CPB 0877
Change Type	Modified
Effective Date	November 1, 2025
Impact Level	High
Specialties Affected	Hematology, Medical Oncology, Infusion Therapy, Revenue Cycle
Key Action	Update prior authorization criteria and charge capture for J9301 to reflect expanded indications before November 1, 2025

---

Aetna Obinutuzumab Coverage Criteria and Medical Necessity Requirements 2025

The updated Aetna obinutuzumab coverage policy covers J9301 across a broader set of indications than prior versions. The real issue here is specificity—Aetna's criteria are combination-regimen dependent. "Obinutuzumab for follicular lymphoma" is not enough. The request must match an approved drug combination.

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Aetna considers obinutuzumab medically necessary for CLL/SLL in two scenarios. First, as a single agent or in combination with acalabrutinib, venetoclax, acalabrutinib plus venetoclax, bendamustine, or chlorambucil (S0172). Second, in combination with high-dose methylprednisolone (J2919, J7509) for CLL/SLL with del(17p) or TP53 mutation—either as first-line therapy or for relapsed/refractory disease.

The del(17p)/TP53 pathway is worth flagging specifically. This is a high-risk cytogenetic subgroup, and prior authorization requests for this combination must include molecular testing documentation. Missing that detail is a direct path to claim denial.

Follicular Lymphoma (FL)

For follicular lymphoma (ICD-10 C82.00–C82.9A), Aetna covers obinutuzumab billing under the following conditions—and the 30-month total treatment cap applies to all of them:

The 30-month cap on follicular lymphoma treatment is a billing detail that will catch teams off guard. Track cumulative treatment duration across claims. If you hit that ceiling and try to continue without documentation of a new indication or appeal, you're looking at a denial.

Marginal Zone Lymphomas

For extranodal marginal zone lymphoma (gastric and non-gastric MALT) and splenic marginal zone lymphoma (C83.00–C83.0A), Aetna covers obinutuzumab when:

#	Covered Indication Copy
1	Used as subsequent therapy with bendamustine or lenalidomide
2	Used as maintenance therapy after prior treatment with obinutuzumab plus bendamustine
3	Used as a rituximab substitute in documented intolerance cases

Nodal marginal zone lymphoma follows a similar pattern—first-line use is covered with CHOP, CVP, or bendamustine combinations. Subsequent therapy follows the same bendamustine or lenalidomide pathway. Maintenance and rituximab-substitute criteria mirror the extranodal criteria.

Prior Authorization and Reimbursement Notes

Obinutuzumab billing under J9301 requires prior authorization on Aetna commercial plans. The medical necessity review will focus on which indication is being treated, which combination regimen is ordered, and whether any prior rituximab use exists (particularly for rituximab-intolerance substitution cases). For Medicare criteria, Aetna defers to the Medicare Part B Step Therapy guidelines—CPB 0877 covers commercial plans only.

---

Aetna Obinutuzumab Exclusions and Non-Covered Indications

The policy doesn't include a formal "experimental" designation for most obinutuzumab uses at this time—but coverage is tightly constrained by combination-regimen rules. Any use of J9301 outside the approved regimen combinations listed above will not meet medical necessity criteria. That's functionally the same as a non-covered indication for claim purposes.

Specifically, watch these edges:

#	Excluded Procedure Copy
1	Follicular lymphoma beyond 30 months — coverage stops at the 30-month total treatment limit unless a new clinical scenario is documented
2	Rituximab-intolerance substitution without documentation — the specific mucocutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, paraneoplastic pemphigus, lichenoid dermatitis, vesiculobullous dermatitis) must be documented. A general note saying "rituximab not tolerated" won't clear the prior auth
3	Off-label combinations — obinutuzumab with agents not listed in the approved combinations is not covered under this policy

---

Coverage Indications at a Glance

---

Aetna Obinutuzumab Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Obinutuzumab Under CPB 0877

Covered HCPCS Codes (When Selection Criteria Are Met)

CPT Codes Related to Obinutuzumab Administration

Key ICD-10-CM Diagnosis Codes

Note: The full policy includes 142 ICD-10-CM codes. The codes above represent the primary diagnosis categories relevant to covered obinutuzumab indications. Pull the complete list from CPB 0877 at app.payerpolicy.org/p/aetna/0877. before finalizing your charge master updates.

---